STRATA Skin Sciences Inc. (NASDAQ:SSKN) and Hologic Inc. (NASDAQ:HOLX), are influenced by contrast since they are both players in the Medical Instruments & Supplies. These factors are particularly influence the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of the two firms.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|STRATA Skin Sciences Inc.||30.49M||2.46||5.59M||5.10||0.46|
In table 1 we can see STRATA Skin Sciences Inc. and Hologic Inc.’s gross revenue, earnings per share and valuation.
Table 2 demonstrates the net margins, return on equity and return on assets of STRATA Skin Sciences Inc. and Hologic Inc.
|Net Margins||Return on Equity||Return on Assets|
|STRATA Skin Sciences Inc.||-18.33%||-20.6%||-13.4%|
Volatility & Risk
STRATA Skin Sciences Inc. is 28.00% more volatile than Standard & Poor’s 500 due to its 1.28 beta. From a competition point of view, Hologic Inc. has a 0.69 beta which is 31.00% less volatile compared to Standard & Poor’s 500.
The Current Ratio and Quick Ratio of STRATA Skin Sciences Inc. are 4.5 and 4 respectively. Its competitor Hologic Inc.’s Current Ratio is 1.4 and its Quick Ratio is 1. STRATA Skin Sciences Inc. can pay off short and long-term obligations better than Hologic Inc.
The table delivered features the ratings and recommendations for STRATA Skin Sciences Inc. and Hologic Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|STRATA Skin Sciences Inc.||0||0||0||0.00|
On the other hand, Hologic Inc.’s potential downside is -7.58% and its average price target is $44.5.
Insider & Institutional Ownership
STRATA Skin Sciences Inc. and Hologic Inc. has shares held by institutional investors as follows: 69.3% and 99.7%. Insiders held roughly 1.38% of STRATA Skin Sciences Inc.’s shares. On the other hand, insiders held about 0.8% of Hologic Inc.’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|STRATA Skin Sciences Inc.||-9.58%||-18.62%||-23.13%||-17.48%||32.58%||-9.23%|
For the past year STRATA Skin Sciences Inc. has -9.23% weaker performance while Hologic Inc. has 9.22% stronger performance.
On 8 of the 12 factors Hologic Inc. beats STRATA Skin Sciences Inc.
STRATA Skin Sciences, Inc., a medical technology company, engages in developing and commercializing products for the treatment of dermatological disorders. Its products include XTRAC and VTRAC devices used for the treatment of psoriasis, vitiligo, and other skin disorders; and MelaFind system, an instrument for aiding dermatologists in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was founded in 1989 and is based in Horsham, Pennsylvania.
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, Procleix family of assays for blood screening, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test. The Breast Health segment offers breast imaging and related products and accessories, including digital and film-based mammography systems; computer-aided detection (CAD) for mammography; invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. This segment also provides Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View that provides a 2D image; Selenia digital mammography platform; and SecurView Workstation. The GYN Surgical segment offers NovaSure system to treat women suffering from abnormal uterine bleeding; and MyoSure system for the hysteroscopic removal of fibroids. The Skeletal Health segment provides discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patientÂ’s extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.